LIGAND PHARMACEUTICALS INC - Common Stock (LGND)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
LGND on Nasdaq
Shares outstanding
19,667,509
Price per share
$189.07
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
20,501,098
Total reported value
$3,631,208,697
% of total 13F portfolios
0.01%
Share change
+1,415,899
Value change
+$253,388,988
Number of holders
307
Price from insider filings
$189.07
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 14% -6.9% $502,945,206 -$18,898,723 2,839,251 -3.6% BlackRock, Inc. 30 Sep 2025
JANUS HENDERSON GROUP PLC 5.3% -3.3% $184,646,839 -$3,251,582 1,042,378 -1.7% JANUS HENDERSON GROUP PLC 30 Sep 2025
As of 30 Sep 2025, LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 307 institutional shareholders filing 13F forms. They hold 20,501,098 shares. .

Top 25 institutional shareholders own 77% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 15% 2,884,527 -1% 0.01% $510,965,112
VANGUARD GROUP INC 11% 2,076,283 -0.63% 0.01% $367,792,771
JANUS HENDERSON GROUP PLC 5.3% 1,042,378 -1.7% 0.08% $184,646,169
MACQUARIE GROUP LTD 3.8% 751,788 -19% 0.16% $133,172,000
STATE STREET CORP 3.8% 749,360 -0.05% 0% $132,741,630
CONGRESS ASSET MANAGEMENT CO 3.4% 667,311 +3% 0.79% $118,207,471
Chicago Capital, LLC 2.9% 568,611 -0.56% 2.5% $100,723,721
Stephens Investment Management Group LLC 2.8% 554,542 -8.3% 1.3% $98,231,570
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 2.8% 541,845 +59% 0.03% $95,982,423
DIMENSIONAL FUND ADVISORS LP 2.7% 523,913 -26% 0.02% $92,798,928
GEODE CAPITAL MANAGEMENT, LLC 2.4% 474,189 -3% 0.01% $84,010,101
FMR LLC 2.3% 457,231 +1644% 0% $80,993,848
LOOMIS SAYLES & CO L P 2% 400,553 -2.5% 0.08% $70,953,958
Invesco Ltd. 1.9% 378,295 +65% 0.01% $67,011,177
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 1.9% 376,601 -3.9% 0.01% $66,711,102
GOLDMAN SACHS GROUP INC 1.9% 367,795 +477% 0.01% $65,151,206
DEUTSCHE BANK AG\ 1.6% 307,532 -0.09% 0.02% $54,476,219
RICE HALL JAMES & ASSOCIATES, LLC 1.5% 294,490 -13% 2.8% $52,165,870
VILLERE ST DENIS J & CO LLC 1.4% 279,950 -2.5% 4.8% $49,590,343
Ranger Investment Management, L.P. 1.4% 275,340 -8.2% 3.4% $48,773,728
NORTHERN TRUST CORP 1.4% 265,962 -3.9% 0.01% $47,112,509
VICTORY CAPITAL MANAGEMENT INC 1.3% 254,805 +677% 0.03% $45,136,158
ASHFORD CAPITAL MANAGEMENT INC 1.2% 244,430 -19% 4.8% $43,298,330
FRANKLIN RESOURCES INC 1.2% 229,856 +24% 0.01% $40,716,692
Private Capital Management, LLC 1.2% 227,158 -0.91% 3.7% $40,238,768

Institutional Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 551,827 $104,383,529 -$36,689,179 $189.07 13
2025 Q3 20,501,098 $3,631,208,697 +$253,388,988 $177.14 307
2025 Q2 19,192,378 $2,181,883,515 +$57,084,248 $113.68 268
2025 Q1 18,695,299 $1,968,273,762 +$46,599,577 $105.14 258
2024 Q4 18,236,878 $1,954,099,547 +$14,647,324 $107.15 255
2024 Q3 18,111,561 $1,812,508,826 +$78,053,426 $100.09 239
2024 Q2 17,257,543 $1,454,006,662 +$80,527,643 $84.26 231
2024 Q1 16,498,593 $1,205,830,157 +$33,853,892 $73.10 220
2023 Q4 16,143,355 $1,152,971,286 +$28,617,779 $71.42 207
2023 Q3 15,788,358 $946,166,941 +$7,782,713 $59.92 194
2023 Q2 15,574,833 $1,123,051,822 +$43,367,440 $72.10 202
2023 Q1 14,933,765 $1,098,173,916 +$24,759,078 $73.56 208
2022 Q4 14,719,986 $983,617,158 -$15,487,378 $66.80 194
2022 Q3 14,858,763 $1,279,578,932 -$9,219,791 $86.11 196
2022 Q2 14,931,494 $1,332,246,388 -$60,732,119 $89.22 183
2022 Q1 15,633,927 $1,758,540,556 -$96,543,968 $112.49 191
2021 Q4 16,269,930 $2,512,534,392 -$20,671,000 $154.46 213
2021 Q3 16,404,211 $2,285,781,890 +$72,094,291 $139.32 203
2021 Q2 15,890,032 $2,084,646,847 +$57,293,258 $131.19 208
2021 Q1 15,419,613 $2,350,478,943 -$1,007,217,320 $152.45 220
2020 Q4 22,774,344 $2,264,990,431 -$7,636,839 $99.45 232
2020 Q3 22,870,335 $2,179,670,768 +$68,808,132 $95.32 248
2020 Q2 22,068,878 $2,469,185,512 -$52,085,687 $111.85 253
2020 Q1 22,949,296 $1,668,870,325 -$13,474,819 $72.72 250
2019 Q4 22,707,169 $2,367,774,479 -$63,568,223 $104.29 254
2019 Q3 23,329,173 $2,322,526,072 -$161,550,967 $99.54 264
2019 Q2 24,903,753 $2,842,785,020 -$64,705,528 $114.15 298
2019 Q1 25,878,742 $3,253,329,789 -$121,262,596 $125.71 321
2018 Q4 26,775,885 $3,634,288,900 +$251,858,628 $135.70 352
2018 Q3 24,242,593 $6,644,377,277 -$319,791,347 $274.49 371
2018 Q2 25,588,124 $5,300,261,339 +$188,038,650 $207.17 341
2018 Q1 24,694,615 $4,066,273,214 +$62,218,325 $165.16 318
2017 Q4 24,690,717 $3,382,790,289 -$24,826,404 $136.93 295
2017 Q3 24,620,963 $3,353,105,420 -$39,757,045 $136.15 289
2017 Q2 25,028,255 $3,037,941,085 +$88,080,338 $121.40 260
2017 Q1 24,696,327 $2,613,964,301 +$250,433,013 $105.84 250
2016 Q4 24,768,649 $2,516,965,895 +$4,668,529 $101.61 264
2016 Q3 24,798,327 $2,528,981,361 +$83,729,768 $102.06 255
2016 Q2 24,659,334 $2,940,759,320 -$22,582,125 $119.27 263
2016 Q1 24,517,182 $2,627,029,783 +$143,212,248 $107.09 248
2015 Q4 23,159,223 $2,510,580,368 +$42,986,460 $108.42 231
2015 Q3 22,765,909 $1,949,890,985 -$18,461,450 $85.65 201
2015 Q2 21,591,797 $2,178,594,586 -$68,365,938 $100.90 213
2015 Q1 22,391,502 $1,726,588,185 +$78,884,093 $77.11 185
2014 Q4 21,661,358 $1,152,510,317 -$4,356,736 $53.21 178
2014 Q3 21,713,346 $1,020,171,713 +$29,265,071 $46.99 173
2014 Q2 20,612,275 $1,283,931,088 -$4,282,796 $62.29 191
2014 Q1 20,823,191 $1,400,767,580 +$26,286,594 $67.26 182